Indication
Rhizomelic Chondrodysplasia Punctata
1 clinical trial
2 products
Product
PPI-1011Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose Study of PPI-1011 in Subjects to Assess Safety, Tolerability, and PharmacokineticsStatus: Recruiting, Estimated PCD: 2023-11-30
Product
Placebo